PLCG2 and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation: On the other hand, APLAID patients, who carry a gain-of-function missense mutation instead of a deletion in the same cSH2 autoinhibitory domain of PLCγ2, have very different cellular and clinical phenotypes.